Sutro Biopharma, Inc. (STRO) Misses Q3 EPS by 7c

Sutro Biopharma, Inc. (NASDAQ: STRO) reported Q3 EPS of ($0.81), $0.07 worse than the analyst estimate of ($0.74). Revenue for the quarter came in at $16.9 million versus the consensus estimate of $12.62 million.

For earnings history and earnings-related data on Sutro Biopharma, Inc. (STRO) click here.

You May Also Be Interested In

• Stitch Fix (SFIX) Tops Q4 EPS by 4c; Offers Guidance
• Cintas beats estimates but stock edges lower
• Cintas Corp. (CTAS) Tops Q1 EPS by 1c, Offers Guidance